Flexiban

Quick links to important sections

Flexiban

Method of action: Miorelaxant, Muscle Relaxant

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flexiban

Property Description
Active ingredient Cyclobenzaprine Hydrochloride
Form Oral Tablet and Oral Capsule
Pharmacological class Centrally Acting Skeletal Muscle Relaxant, CNS Depressant
Common use Adjunctive therapy for acute, painful muscle spasms
Origin Synthetic Compound

What Type of Medicine is Cyclobenzaprine (Flexiban)?

Flexiban is the trade name for the prescription medicine containing the active ingredient Cyclobenzaprine Hydrochloride. It is classified as a centrally acting skeletal muscle relaxant and a type of Central Nervous System (CNS) depressant. This medication is a synthetic compound chemically related to tricyclic compounds, a feature distinguishing it from other skeletal muscle relaxants. As a single-ingredient product, it is administered orally as a systemic agent, meaning its therapeutic effects are distributed via the bloodstream to provide general relief from musculoskeletal issues, unlike topical medicines that only act locally.


How Does Cyclobenzaprine Work on Muscle Spasm?

The general purpose of this medicine is to help relieve the painful symptoms and stiffness associated with acute muscle spasms that often occur following injury or strain. Cyclobenzaprine acts centrally, working on control centers in the brain stem and spinal cord to modulate the nerve signaling that causes excessive muscle tightening, rather than working directly on the muscle fibers themselves. By reducing this overactive motor nerve activity, the drug helps to interrupt the cycle of pain and spasm. Pharmacological studies consistently support its role in easing muscle hyperactivity, facilitating patient comfort during recovery from conditions like severe muscle stiffness in the lower back. This means the medication primarily targets the nervous system to ease muscle stiffness.


What Forms and Composition Does Flexiban Use?

Cyclobenzaprine Hydrochloride is administered as an oral dosage form, available as both an immediate-release tablet and an extended-release capsule. The composition includes the active ingredient combined with various solid excipients (inactive ingredients) necessary for forming the dosage unit, such as cellulose and magnesium stearate. The availability of both an immediate-release and an extended-release form is a key feature, allowing for different therapeutic dosing schedules. The oral route of administration ensures that the active compound is absorbed into the bloodstream, allowing it to exert its intended systemic effects on the central nervous system to manage muscle hyperactivity.

What side effects are possible with Flexiban?

Adverse Reactions and Safety Information

Flexiban (cyclobenzaprine hydrochloride) is a skeletal muscle relaxant structurally related to tricyclic antidepressants. Its safety profile involves Central Nervous System (CNS) depressant and anticholinergic effects, and the potential for serious cardiovascular events.


Common Side Effects

The most frequently reported adverse reactions include somnolence (drowsiness), dry mouth, dizziness, fatigue, and gastrointestinal effects such as constipation, nausea, and dyspepsia (indigestion). Drowsiness and dry mouth are reported most often and may be dose-related.


Serious Adverse Reactions and Warnings

Serious, potentially life-threatening reactions require immediate medical attention:

  • Serotonin Syndrome: A severe condition that may occur, particularly with concomitant use of other serotonergic drugs (e.g., SSRIs, MAO inhibitors). Symptoms include confusion, agitation, hallucinations, autonomic instability (rapid heart rate, fever, sweating), and neuromuscular abnormalities (tremor, muscle rigidity).
  • Cardiovascular Effects: Due to its tricyclic antidepressant-like properties, the drug has the potential to cause or exacerbate cardiac conditions such as arrhythmias, sinus tachycardia, conduction disturbances, myocardial infarction, and stroke.

Contraindications and Safety Restrictions

Flexiban is contraindicated in patients with a history of hypersensitivity, recent acute recovery phase of myocardial infarction, congestive heart failure, arrhythmias, or hyperthyroidism. Its use is also strictly prohibited concurrently with, or within 14 days of discontinuing, a Monoamine Oxidase Inhibitor (MAOI).

Use is generally restricted to short periods (up to two or three weeks). Geriatric patients (65 years and older) and individuals with moderate to severe hepatic impairment are generally not recommended to use this medication due to increased plasma levels and susceptibility to adverse effects.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of cyclobenzaprine (Flexiban) is officially documented to present with a range of manifestations, primarily affecting the Central Nervous System and the cardiovascular system. The most commonly reported clinical signs of toxicity include drowsiness and tachycardia (fast heart rate). Less common but severe documented presentations include agitation, confusion, hallucinations, seizures, and coma.

Serious Outcomes and Emergency Action

Official regulatory information emphasizes the risk of potentially life-threatening outcomes, such as cardiac dysrhythmias, severe hypotension, and cardiac arrest. The official label also notes the risk of Serotonin Syndrome when cyclobenzaprine is co-administered with other serotonergic agents.

Seeking immediate medical attention is required for any suspected overdose. The official guidance states that one must immediately call emergency services if the person has collapsed, had a seizure, is unconscious, or has trouble breathing.

Management is documented to be symptomatic and supportive, and no specific antidote is known. Due to the potential for delayed, serious cardiovascular events, hospital monitoring is required to check for complications, including changes in the ECG.

Therapeutic Uses of Flexiban

The medication Flexiban (Cyclobenzaprine) is commonly used to provide targeted symptomatic relief for acute, painful muscle spasms. The medication is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions.


Easing Acute, Painful Muscle Spasms

Flexiban is commonly used as adjunctive therapy for acute, painful muscle spasms that often follow specific injuries, strains, or localized trauma. This includes symptoms such as stiffness and localized pain, which may lead to temporary restriction in movement. It is applied when spasms cause significant discomfort, helping to address symptoms related to heightened physiological activity.

“This medication is typically used on a short-term basis to support the patient during the most difficult phases of acute muscle spasm.”

This symptomatic support is relevant for managing the symptom clusters associated with short-term musculoskeletal conditions, like acute low back pain or neck pain due to strain. By addressing the pronounced muscle symptoms, it contributes to easing day-to-day comfort and supports the patient during episodes of heightened discomfort.


Quick Fact: Relief for Acute Muscle Spasms

The main benefit of Flexiban is providing supportive relief that assists with maintaining comfort when muscle tension and associated pain interfere with routine activities.

Regulatory References

  1. DailyMed drug information from the National Institutes of Health

Eligibility and Restrictions for Use

Flexiban (Cyclobenzaprine) eligibility is strictly defined by regulatory documents, distinguishing between approved, conditional, and prohibited populations. The medicine is generally established for adults (aged 18 and older) for short-term use (up to two or three weeks). Use is not recommended in children under 15 years of age because safety and effectiveness have not been established. Use is also not recommended for geriatric patients (aged 65 and older) due to increased exposure and risk.


Contraindicated Populations (Must Not Use) Condition-Specific Restrictions
Monoamine Oxidase (MAO) inhibitors (or within 14 days of use) Moderate or Severe Hepatic Impairment (Use not recommended)
Acute recovery phase of myocardial infarction (heart attack) Mild Hepatic Impairment (Use with caution for IR tablet)
Congestive heart failure or certain heart rhythm disorders History of Urinary Retention or Angle-Closure Glaucoma (Use with caution)
Hyperthyroidism or known Hypersensitivity to the drug Pregnancy: Use only if clearly needed; Lactation: Use with caution

The regulatory profile clearly excludes patients with specific cardiovascular issues, a history of hypersensitivity, or concurrent/recent MAOI therapy. The requirements for conditional use address specific vulnerabilities, such as impaired liver function and anticholinergic sensitivity.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Flexiban (cyclobenzaprine) has several officially documented interaction patterns, primarily involving additive effects on the central nervous system (CNS) and metabolic considerations.


Formal Contraindications and Restrictions

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated due to the risk of severe reactions, including hyperpyretic crisis and seizures. The official regulatory documents require a 14-day separation period after stopping an MAOI before cyclobenzaprine can be administered.


Pharmacodynamic and CNS Effects

Cyclobenzaprine may enhance the effects of other CNS Depressants, such as alcohol (ethanol), barbiturates, and opioids, resulting in potentiation of sedation and dizziness. Concomitant use with serotonergic agents (e.g., SSRIs, SNRIs) is associated with the risk of Serotonin Syndrome. The drug's anticholinergic properties can also lead to enhanced anticholinergic adverse effects when combined with other anticholinergic medicines.


Exposure and Population Sensitivity

For the extended-release capsule, co-administration with food results in a documented increase in systemic exposure (AUC and C max). Furthermore, patients with hepatic impairment and the elderly (ge 65 years) exhibit significantly higher plasma levels due to reduced clearance, a population-specific sensitivity noted in regulatory labeling. Cyclobenzaprine is primarily metabolized by CYP enzymes 3A4, 1A2, and 2D6.

Mechanism of Action

Modulating Descending Motor Control Pathways

The primary action of Cyclobenzaprine is the antagonism of Serotonin 5-HT 2A receptors located within the brain stem, specifically targeting the descending neuronal pathways involved in motor activity. By dampening the excitatory signals that travel from the brain stem to the spinal cord, the drug results in a reduction in the excitability of alpha (alpha) and gamma (gamma) motor neurons. This central modulation reduces the excessive nerve outflow that facilitates tonic motor activity.

Mechanistic Specificity in Modulating Tonic Motor Activity

This central modulation results in the physiological consequence: the depression of tonic somatic motor activity. This mechanism modulates the activity patterns characteristic of local musculoskeletal overactivity and does not rely on direct action at the muscle fiber or neuromuscular junction. The mechanism demonstrates functional limitations against motor hypertonia caused by established central nervous system pathologies.

Contributing CNS Depressant Actions

Cyclobenzaprine also exhibits high affinity for antagonizing Histamine H1 receptors in the central nervous system. This off-target interaction contributes to a generalized central sedation by suppressing CNS arousal pathways, which further supports the overall suppression of motor outflow.

Dosage and Administration Information

How to Use Cyclobenzaprine

Cyclobenzaprine (Flexiban) is administered exclusively by the oral route and is intended for short-term use only, typically limited to a course of two or three weeks. It is available as an immediate-release (IR) tablet and an extended-release (ER) capsule, with schedules defined by the specific form.


Dosing and Administration

Both the IR tablet and the ER capsule may be taken with or without food.

Dosage Form Standard Regimen Frequency and Max Dose
IR Tablet Starting dose of 5 mg, up to 10 mg per dose. Taken three times daily; maximum daily dose is 60 mg.
ER Capsule Doses are 15 mg or 30 mg. Taken once daily, ideally at the same time each day.

For the extended-release capsule, patients must swallow the capsule whole. Alternatively, the contents may be carefully emptied onto a tablespoon of applesauce and swallowed immediately without chewing; the capsule or its contents must not be crushed.


Population-Specific Instructions

Prescribing information includes specific instructions for certain patient populations. For older adults (age 65 and over), therapy with the immediate-release form should be initiated at 5 mg with a slow titration schedule and less frequent dosing considered. The extended-release form is not recommended for older adults or patients with moderate to severe hepatic impairment. Use of the IR tablet is approved for patients 15 years of age and older using the standard adult dosing regimen.

Recent Clinical Evidence

Research evidence / Overview of studies for Flexiban

Evidence for Use in Acute Muscle Spasm

The majority of formal clinical research on cyclobenzaprine has focused on symptoms associated with acute, painful muscle spasms. This evidence is built primarily upon short-term, randomized controlled trials (RCTs) and systematic reviews. These studies were designed to explore how symptoms change over time during a temporary episode, typically lasting less than three weeks, often involving low back or neck pain.

Researchers examined various outcomes related to physical discomfort and functional imbalance. These included patient-reported outcomes describing perceived discomfort, such as overall global change and changes in patient-reported scores for pain and muscle tightness. Trials reported on the analysis of mean scores, which showed differences between groups receiving cyclobenzaprine and those receiving placebo on measures like patient global impression. Studies examining the combination of cyclobenzaprine with an NSAID did not consistently show a statistically significant difference in patient-rated efficacy when compared to either drug used alone in certain observed populations.


Evidence for Cyclobenzaprine in Fibromyalgia

Cyclobenzaprine was also evaluated in research exploring its relevance for symptoms associated with fibromyalgia. These investigations typically involved intermediate-term RCTs that focus on multiple symptom domains.

In this research context, studies explored outcomes related to sleep quality, fatigue, overall patient global impression, and pain reduction scores. Pooled analyses of studies reported on observed patterns of change in some outcomes when compared to placebo. However, the reported outcomes for core functional measures for fibromyalgia showed mixed findings or differences that were small when compared to placebo. Research provides context but not individual predictions.


Long-Term Studies and Follow-up Duration

The follow-up durations for the main clinical trials examining acute muscle spasm relief were limited and generally did not extend beyond two to three weeks. Evidence is limited for prolonged use. Official information states that adequate evidence of effectiveness for more extended use is not available. Consequently, long-term outcomes are not fully established, and there is limited information regarding the durability of any observed changes or the benefit of using the drug for chronic (long-lasting) conditions.

Frequently Asked Questions (FAQ)

Common questions about Flexiban (FAQ)

Q: How quickly does Flexiban start to work after taking it?

A: Official information for the immediate-release tablet suggests that some muscle-relaxing effects may become noticeable within 30 minutes to one hour after administration. However, the full effect for acute spasms may require up to approximately 7 days of therapy, according to clinical observation.

Q: How long does the effect of Flexiban typically last?

A: Flexiban's active ingredient is generally associated with an average half-life of 18 hours, which describes how long it takes for half the medicine to leave the bloodstream. For the immediate-release tablet form, the muscle relaxant effect is generally associated with a duration of 4 to 6 hours.

Q: Is Flexiban a type of painkiller?

A: Flexiban is officially classified as a centrally acting skeletal muscle relaxant. It is indicated for the relief of muscle spasm associated with acute, painful musculoskeletal conditions. Therefore, its primary role is as a muscle relaxant, although it helps alleviate painful symptoms associated with muscle spasms.

Q: Is Flexiban known to cause weight gain?

A: Official documents note both weight gain and weight loss have been reported rarely. However, a definitive cause-and-effect relationship between the medicine and these weight fluctuations has not been established in the regulatory data.

Q: Can Flexiban cause sleep problems or insomnia?

A: Yes, insomnia (difficulty falling or staying asleep) is listed in regulatory documents as a reported side effect of cyclobenzaprine. The most frequently reported central nervous system side effects are actually somnolence (drowsiness) and fatigue.

Q: Are there any known long-term side effects associated with Flexiban use?

A: The medication is approved for short periods, typically limited to two or three weeks. Official documentation states that adequate evidence of effectiveness for more prolonged use is not available. This limitation means that the long-term safety profile and potential adverse effects of using the drug over an extended period are not fully established.

Q: Does Flexiban affect a person's ability to drive?

A: Official patient information indicates that cyclobenzaprine may impair the mental or physical abilities required for performing hazardous tasks. This warning covers activities such as operating machinery or driving a motor vehicle.

Q: What happens if a dose of Flexiban is missed?

A: Regulatory guidance describes two principles for dealing with a missed dose. If a dose is missed, patients are generally advised to take it as soon as remembered, unless it is almost time for the next scheduled dose. In that case, the patient should continue with the regular schedule, and not double up on doses.

Q: Is Flexiban considered a controlled substance?

A: No, according to the U.S. Drug Enforcement Administration (DEA), cyclobenzaprine (Flexiban) is not classified as a controlled substance under the Controlled Substances Act.

Q: Are there any specific dietary restrictions when taking Flexiban?

A: There are generally no specific dietary restrictions noted in regulatory documents that apply to the general patient population. However, patients are specifically advised to avoid alcohol consumption, as it can enhance the medicine’s central nervous system depressant effects.

Q: What is the difference between Flexiban and other types of muscle relaxants?

A: Flexiban's active ingredient is chemically related to tricyclic antidepressants (TCAs), which gives it a distinct pharmacological profile. Its action is primarily central, meaning it works by modulating nerve signals in the brain stem and spinal cord, rather than having a direct effect on muscle fibers.

Q: Is Flexiban effective for muscle spasms caused by nerve injury?

A: Official prescribing information states that the medicine is not effective for muscle spasticity or spasms caused by central nervous system diseases (e.g., cerebral palsy). The drug's approved use is limited to muscle spasms associated with acute, painful musculoskeletal conditions.

Q: What should be done if an allergic reaction is suspected while taking Flexiban?

A: Serious hypersensitivity reactions (allergic reactions), including swelling of the skin and airways (angioedema) and anaphylaxis, have been reported in official documents. Patients experiencing these reactions should immediately seek emergency medical attention, as these are considered serious events.

Q: Can Flexiban be taken with anti-anxiety medications?

A: Regulatory documents advise caution regarding co-administration with other Central Nervous System (CNS) depressants. This includes many medications used for anxiety, such as benzodiazepines, because combining these drugs may lead to enhanced side effects such as drowsiness and dizziness.

Q: Does Flexiban have a risk of dependence or withdrawal symptoms?

A: The drug has not been formally associated with physical addiction or abuse properties. However, official information indicates that if the medicine is used for an extended period, abruptly stopping it may lead to temporary discontinuation symptoms such as nausea, headache, and general malaise (discomfort).

Q: Are headaches a common side effect of Flexiban?

A: Yes, headache is listed in the official documents as an adverse effect that was commonly reported during clinical studies. It is noted alongside other frequent side effects such as drowsiness and dry mouth.

Q: Does Flexiban affect blood pressure?

A: Due to its structural properties, the medicine has the potential to affect cardiovascular status, with reports of both hypotension (low blood pressure) and hypertension (high blood pressure) noted in official documents.

Q: Is Flexiban only for pain relief or does it help with movement too?

A: Flexiban is indicated for the relief of muscle spasm and its associated signs and symptoms. These symptoms include not only pain and tenderness but also limitation of motion and restriction in activities of daily living. By reducing muscle hyperactivity, the medicine is intended to help improve comfort and facilitate movement.

Q: Can Flexiban be used if I have kidney problems?

A: The active ingredient of Flexiban is extensively metabolized in the liver, and its breakdown products are primarily excreted through the kidney. Because the breakdown products are primarily excreted through the kidney, careful review is generally necessary for individuals with reduced kidney function due to the potential for drug accumulation.

Q: Does Flexiban show up on a standard drug test?

A: Cyclobenzaprine is structurally similar to tricyclic antidepressants (TCAs). Although Flexiban is not typically a target drug in standard drug screening tests, its structural similarity means it could potentially trigger a false positive result for tricyclic antidepressants.

Q: What is the role of Flexiban in physical therapy?

A: Flexiban is explicitly indicated as an adjunct to rest and physical therapy for the relief of muscle spasm. This means the medicine is intended to be used temporarily alongside non-drug treatments like physical therapy, not as a standalone treatment.

Q: How is Flexiban eliminated from the body?

A: Flexiban undergoes extensive metabolism (chemical breakdown) primarily in the liver through specific enzymes. After this breakdown, the resulting products are mainly excreted from the body via the kidneys in the urine.

Q: Are there special monitoring requirements for patients taking Flexiban?

A: While continuous monitoring may not be required for every patient, regulatory documents highlight the drug's potential for cardiovascular effects. In cases of overdose, for instance, ECG (electrocardiogram) and comprehensive cardiac monitoring are necessary due to the tricyclic-like nature of the compound.

Q: Are there any known issues with stopping Flexiban suddenly?

A: Official patient information notes that if the drug is used for an extended period, abruptly discontinuing the medication may result in temporary symptoms. These reported symptoms include nausea, headache, and a general feeling of malaise (discomfort).

How should Flexiban be stored and disposed of?

Flexiban (cyclobenzaprine hydrochloride) must be stored at Controlled Room Temperature, defined as 20°C to 25°C (68°F to 77°F), with permitted excursions up to 30°C. The medication must be kept in a tight, light-resistant container and secured with a child-resistant closure. As a mandatory safety requirement, Flexiban must be stored out of the reach of children.


For disposal, Flexiban is not on the FDA's flush list. The preferred method for discarding unused or expired product is a drug take-back program. If a take-back option is unavailable, the medicine should be mixed with an unpalatable substance (like coffee grounds or dirt) and sealed in a container before being placed in the household trash. Any unused portion of the extended-release capsule contents mixed with food must be immediately discarded.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flexiban found in:

A-Z Index: